Flputnam Investment Management Co. Purchases 543,370 Shares of Cardiff Oncology, Inc. $CRDF

Flputnam Investment Management Co. lifted its position in Cardiff Oncology, Inc. (NASDAQ:CRDF) by 1,008.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 597,233 shares of the company’s stock after purchasing an additional 543,370 shares during the quarter. Flputnam Investment Management Co. owned about 0.90% of Cardiff Oncology worth $1,230,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Engineers Gate Manager LP purchased a new position in Cardiff Oncology during the second quarter worth about $43,000. BNP Paribas Financial Markets boosted its position in shares of Cardiff Oncology by 335.1% during the 2nd quarter. BNP Paribas Financial Markets now owns 15,437 shares of the company’s stock valued at $49,000 after acquiring an additional 11,889 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Cardiff Oncology by 189.3% during the second quarter. Bank of America Corp DE now owns 93,393 shares of the company’s stock worth $294,000 after purchasing an additional 61,110 shares in the last quarter. Glenview Trust co increased its position in shares of Cardiff Oncology by 79.9% in the second quarter. Glenview Trust co now owns 43,128 shares of the company’s stock worth $136,000 after purchasing an additional 19,150 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in Cardiff Oncology by 23.9% in the second quarter. The Manufacturers Life Insurance Company now owns 21,956 shares of the company’s stock valued at $69,000 after purchasing an additional 4,232 shares in the last quarter. Institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Trading Up 13.6%

Shares of NASDAQ CRDF opened at $2.92 on Tuesday. The stock’s 50-day moving average is $2.26 and its 200 day moving average is $2.64. The stock has a market cap of $196.69 million, a price-to-earnings ratio of -3.70 and a beta of 1.35. Cardiff Oncology, Inc. has a 1-year low of $1.90 and a 1-year high of $4.99.

Cardiff Oncology (NASDAQ:CRDF) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.03. The business had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $0.12 million. Cardiff Oncology had a negative net margin of 10,064.27% and a negative return on equity of 77.21%. On average, analysts forecast that Cardiff Oncology, Inc. will post -0.99 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $10.83.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.